Open Access

Terminalia paniculata bark extract attenuates non-alcoholic fatty liver via down regulation of fatty acid synthase in high fat diet-fed obese rats

  • Mopuri Ramgopal1,
  • Banavathy S Kruthika2,
  • Damineni Surekha2 and
  • Balaji Meriga1Email author
Lipids in Health and Disease201413:58

DOI: 10.1186/1476-511X-13-58

Received: 17 December 2013

Accepted: 17 March 2014

Published: 29 March 2014



This study was performed to understand the possible therapeutic activity of Terminalia paniculata ethanolic extract (TPEE) on non alcoholic fatty liver in rats fed with high fat diet.


Thirty six SD rats were divided into 6 groups (n = 6): Normal control (NC), high fat diet (HFD), remaining four groups were fed on HFD along with different doses of TPEE (100,150 and 200 mg/kg b.wt) or orlistat, for ten weeks. Liver tissue was homogenized and analyzed for lipid profiles, activities of superoxide dismutase (SOD), catalase (CAT) and malondialdehyde (MDA) content. Further, the expression levels of FAS and AMPK-1α were also studied in addition to histopathology examination of liver tissue in all the groups.


HFD significantly increased hepatic liver total cholesterol (TC), triglycerides (TG), free fatty acids (FFA) and MDA but decreased the activities of SOD and CAT which were subsequently reversed by supplementation with TPEE in a dose-dependent manner. In addition, TPEE administration significantly down regulated hepatic mRNA expression of FAS but up regulated AMPK-1α compared to HFD alone fed group. Furthermore, western blot analysis of FAS has clearly demonstrated decreased expression of FAS in HFD + TPEE (200 mg/kg b.wt) treated group when compared to HFD group at protein level.


Our biochemical studies on hepatic lipid profiles and antioxidant enzyme activities supported by histological and expression studies suggest a potential therapeutic role for TPEE in regulating obesity through FAS.


High fat diet Liver lipid profile Superoxide dismutase Catalase Malondialdehyde FAS AMPK-1α Histopathology


Obesity is a well known risk factor for a variety of life style disorders, such as type 2 diabetes, hyperlipidemia, atherosclerosis, cardiovascular diseases and certain cancers [1, 2]. It is characterized by accumulation of excess fat in the body and dysregulation of lipid metabolism [3]. The role of fatty acid synthase is implicated in the regulation of fatty acid synthesis and net accumulation of lipid in liver and adipose tissue [4]. Previous studies showed that high fat diets result in non- alcoholic hepatic steatosis (NAHS). Nearly 70-90% of the non alcoholic fatty liver problems were observed in obese and diabetic patients. The NAHS is characterized by accumulation of excessive triacylglycerol (TAG) within hepatocytes and the condition can progress into more serious liver diseases, such as liver fibrosis, cirrhosis, non alcoholic steatohepatites [46]. A few pharmaceutical synthetic drugs, fibrates and statins are available to treat obesity. However due to adverse side effects they are not preferred for long time usage [7]. Therefore, attempts are being made to develop natural product-based safe and effective drugs to treat obesity [8, 9].

Terminalia paniculata Roth. (Combretaceae) is a tropical tree with a large natural distribution in western and southern parts of India. Traditionally, flower juice and bark of T. paniculata have been used to treat cholera, inflammation of parotid glands and menstrual disorders [10], cough, bronchitis, cardiac debility, hepatitis and diabetes and it has spermicidal activity too [1113]. Phytochemicals such as Ellagic acid, Dimethylellagic acid, Pentamethyl flavellagic acid, Trimethyl flavellagic acid and β-Sitosterol have been isolated from the heartwood of T. paniculata. The bark was reported to contain 14% tannins which have a pyrogallol nucleus along with gallic acid [14]. The anti oxidant activity of this plant was evaluated with DPPH (2, 2 Diphenyl-1-picrylhydrazyl) by Shalu et al. [15]. Till now there are only few reports about the therapeutic activity of Terminalia paniculata and its phytochemicals, but there are hardly any reports in understanding the anti-obesity activity of this plant. Hence, our present work was aimed to investigate the protective effect of TPEE in non alcoholic fatty liver development and to understand the role of genes such as FAS and AMPK-1α in HFD-fed obese rats.


Measurement of body and organ weights

After the end of the experimental period, rats were weighed and body weights noted. HFD-fed rats showed substantial raise in body weight gain, compared to normal control group. However, HFD + TPEE (100, 150 and 200 mg/kg b.wt) administered rats showed significant decrease in weight gain compared to HFD control group (Table 1). Table 1 compares and explains body and organ weights of different groups. The liver and kidney weights of HFD-fed rats increased considerably which were significantly (p < 0.05) and dose dependently reduced by TPEE treatment. Whereas spleen and testis of TPEE treated groups did not show any significant variation compared to HFD control.
Table 1

Effect of TPEE on body and organ weights of control and HFD-fed rats






Body weight


8.169 ± 1.2

1.693 ± 0.5

0.593 ± 0.2

2.443 ± 0.6

235 ± 3.02


11.73 ± 1.3#

2.884 ± 0.4#

0.664 ± 0.1

2.83 ± 0.4

460 ± 1.26#


7.462 ± 1.1*

1.80 ± 0.5*

0.5 ± 0.3

2.698 ± 0.8

340 ± 2.41*


9.919 ± 0.5

2.97 ± 0.3

0.502 ± 0.2

2.803 ± 0.5

425 ± 5.01


8.69 ± 0.5*

2.0 ± 0.3*

0.50 ± 0.2

2.803 ± 0.5

380 ± 1.49*


7.01 ± 0.5*

1.62 ± 0.5*

0.50 ± 1.5

2.71 ± 0.9

350 ± 1.10*

The data are given as mean ± S.D (n = 6). *(P < 0.05). Values are tested by ANOVA with Duncan’s multiple range tests. #P < 0.05 significantly different from normal control, *P < 0.05 significantly different from HFD control NC: Normal control group, HFD: high-fat diet group, ORL: Orlistat, TPEE: T.Paniculata ethanolic extract (100,150 and 200 mg/kg b.wt/day).

Hepatic lipid profiles

To determine the effect of TPEE on hepatic lipid profiles, we estimated total cholesterol (TC), triglycerides (TG) and free fatty acids (FFA) in all groups of rats. Table 2 compares and explains lipid profiles of different groups. TPEE + HFD (100, 150 and 200 mg/kg b.wt) administered rats showed reduced TC (12.5%, 26.5% and 39%), TG (15%, 26% and 42%) and FFA (16%, 35% and 56%) levels when compared to HFD fed control group (Table 2). The above results demonstrated that TPEE at a dose of 200 mg/kg b.wt showed similar activity as that of HFD + orlistat treated group.
Table 2

Effect of TPEE on liver lipid levels of control and HFD-fed rats


Total cholesterol


Free fatty acids


2.32 ± 0.25

78.83 ± 6.85

5.8 ± 1.15


4.60 ± 0.25#

171.8 ± 9.2#

12.6 ± 2.4#


2.38 ± 0.21*

90 ± 11.0*

4.42 ± 1.17*


4.10 ± 0.24

151 ± 10.7

10.5 ± 1.70


3.67 ± 0.27*

137.6 ± 6.2*

8.5 ± 1.67*


2.87 ± 0.15*

99 ± 10.8*

5.5 ± 2.12*

F Value








The data are expressed as the mean ± S.D (n = 6). Values are tested by ANOVA with Duncan’s multiple range tests. #P < 0.05 significantly different from normal control, *P < 0.05 significantly different from HFD control. NC: Normal control group, HFD: high-fat diet group, ORL: Orlistat, TPEE: T. Paniculata ethanolic extract (100, 150 and 200 mg/kg/day).

Activity of liver antioxidant enzymes

To determine the in vivo antioxidant activity, the levels of superoxide dismutase (SOD), catalase (CAT) and malondialdehyde (MDA) content were estimated from the liver tissue. There was a substantial decrease in the activity of SOD and CAT but raise in MDA content in HFD-fed groups. However, TPEE (100, 150 and 200 mg/kg b.wt) administration has significantly reversed these alterations in SOD, CAT and MDA levels. At a dose of 200 mg/kg b.wt, TPEE increased the activity of SOD and CAT by 62% and 53% respectively but decreased MDA content by 49% as shown in Figure 1.
Figure 1

Effect of TPEE on (A) SOD activity (B) CAT activity and (C) MDA content in liver. The data are expressed as the mean ± S.D (n = 6). Values were tested by ANOVA with Duncan’s multiple range test. *P < 0.05 significantly different from HFD control. NC: Normal control group, HFD: high-fat diet group, TPEE: T. paniculata ethanolic extract (100,150 and 200 mg/kg b.wt/day).

Effect of TPEE on expression of FAS and AMPK-1α by RT-PCR

As showed in Figure 2, HFD caused up regulation of fatty acid synthase (FAS) expression at mRNA level which was subsequently down regulated by TPEE (100, 150 and 200 mg/kg b.wt) administration (Figures 2A and B). On the contrary, mRNA expression of AMPK-1α was down regulated by HFD, but, this was up regulated by TPEE administration in a dose dependent manner (Figures 3A and B).
Figure 2

Effect of TPEE on expression of FAS mRNA in control and HFD-fed rats. (A) Gene expression of FAS. (B) Densitometric values of FAS. The values are expressed as mean ± S.D.
Figure 3

Effect of TPEE on expression of AMPK-1α mRNA in control and HFD-fed rats. (A) Gene expression of AMPK-1α. (B) Densitometric values of AMPK-1α. The values are expressed as mean ± S.D.

Western blot analysis for FAS expression

To further validate our results, we conducted western blot analysis of FAS, a central enzyme in fatty acid synthesis. As depicted in Figure 4, FAS expression was up regulated in HFD-fed rats where as HFD + TPEE (200 mg/kg body weight) administrated group showed down regulated level of FAS.
Figure 4

Effect of TPEE on western blot analyses of FAS in control and HFD-fed rats.

Histopathological studies of liver

To evaluate the active role of TPEE on hepatic steatosis we have examined the Hematoxylan and Eosin stained liver microtome sections. HFD-fed control group rats showed higher accumulation of lipid droplets, loss of nucleus, inflammatory cells and severe swelling of hepatocytes, indicating hepatic steatosis. However, HFD + TPEE treated groups showed decreased lipid accumulation, lesser damage and near normal hepatocytes (Figure 5).
Figure 5

Effect of TPEE on liver morphology and histopathology in control and HFD-fed rats. NC: Normal control group, HFD: high-fat diet group, ORL: Orlistat, TPEE: T. paniculata ethanolic extract (100,150 and 200 mg/kg b.wt/day).


The non alcoholic fatty liver (NAFL) and its progressive form non alcoholic steatohepatities (NASH) is a common liver disorder found in dislipidemic and obese conditions. In one end the NAFL, NASH pathological spectrum of steatosis viewed as without inflammation or necrosis, but on the other hand its progression appeared with inflammation, necrosis and liver cirrhosis [16]. In the present study, significant increase in the weights of liver and kidney, elevated hepatic total cholesterol, triglycerides and free fatty acids were noticed in addition to body weight gain in HFD-fed rats. This is in agreement with previous studies on HFD fed rats [5, 17]. In the present study we used three concentrations of TPEE (100, 150 and 200 mg/kg b.-wt) on HFD-fed rats. We observed dose dependent activity of these extracts. Among the three doses administered 200 mg/kg b.wt of TPEE was able to significantly (P < 0.05) reduce gain in body weight, organ weights, as well as TC, TG and FFA. This suggests a potential role for TPEE in regulation of fatty acid synthesis, fat accumulation and adipogenesis by modulating key lipogenic factors such as FAS, AMPK-1α and other transcriptional regulators [18]. Previous reports showed that HFD induces oxidative stress, consequential damage of membrane lipids, proteins and other macro molecules [18]. It is a known fact that in enzymatic reactions, SOD converts superoxide anions to H2O2 (hydrogen peroxide) and the released H2O2 can be degraded by CAT to H2O [19]. In our study HFD-induced drop in the activity of SOD and CAT but elevated MDA content was noted in HFD-fed rats. But in HFD + TPEE (100, 150 and 200 mg/kg b.wt) administered rats, raise in SOD and CAT activity but fall in MDA level was noticed suggesting potent antioxidant property of TPEE. Elevated SOD and CAT levels in TPEE treated groups could effectively scavenge the reactive oxygen species (ROS) and thus minimized lipid peroxidation. In addition, HFD, devoid of TPEE could cause dysregulated secretion and release of adipocytokines that might contribute to steatohepatites and hepatic inflammation [20, 21]. Transcription factors such as PPARs and SREBPs are involved in regulation of lipid homeostasis by activating the expression of genes required for the synthesis and uptake of cholesterol, fatty acids and triglycerides. Particularly, SREBP-1c, one of the pro adipogenic transcription factors, regulates the expression of FAS and AMPK-1α which play important role in regulation of lipid and carbohydrate metabolism through lipogenesis and uptake of glucose [22, 23]. To support our results, we have carried out semiquantitatve reverse transcriptase PCR analysis of important lipogenic genes such as FAS and AMPK-1α in hepatic tissue. We have found down regulation of FAS expression in HFD + TPEE treated groups whose expression was otherwise increased in HFD-fed group. On the contrary, the expression of AMPK-1α was up regulated in HFD + TPEE treated groups which was otherwise down regulated in HFD-fed rats. To further confirm the role of FAS in lipogenesis and fatty liver development, we performed western blot analysis for FAS expression. TPEE (200 mg/kg b.wt) administration has significantly down regulated the expression of FAS at protein level in hepatic tissue. This confirms that FAS expression was controlled possibly at transcriptional level through PPARs and SREBPs mediated signaling path way. In fact, our results on TPEE-mediated down regulation of expression of PPAR-γ and SREBP-1c also supported this event (data not shown here). Furthermore, histopathological examination of liver sections have clearly demonstrated the appearance of normal hepatocytes with reduced lipid droplets in HFD + TPEE treated groups. Further studies are needed to isolate the actual lead molecules from TPEE and to understand the exact mechanism behind their activity.


Based on our biochemical, histopathological and expression studies, we demonstrate that TPEE potentially attenuates development of non alcoholic fatty liver and obesity.

Materials and methods

Collection and extraction of plant material

The bark of Terminalia paniculata was collected from Seshachalam forest spread around Tirupati, Andhra Pradesh, India. Its identity was authenticated by a Taxonomist, Department of Botany, at S.V. University, Tirupati, voucher number 136, and a specimen has been preserved at the departmental herbarium. The bark of T. paniculata was dried under shade, pulverized to coarse powder and extracted with ethanol. The filtrate obtained was evaporated to dryness at 50-65°C in a rotary vacuum evaporator to obtain a dark colored molten mass.


For this study, male Sprague–Dawley rats (n = 36), weighing 150-160 g were obtained from National Institute of Nutrition, Hyderabad, India. All rats were housed under 22 ± 2°C temperature, humidity (40-50%) and light–dark cycle (12-12 ± 1 h) and allowed food and water ad libetum, for ten weeks. Experimental protocols were followed as per Institutional animal ethics committee guidelines (IAEC) (Regd No: 438/01a/CPCSEA, Date: 17-07-2001). The Committee granted permission to authors and passed resolution to carryout animal work (Resolution No: 36/2012-2013/ (i)/a/CPCSEA/IAEC/SVU/MB-MRG).

Composition of high fat diet

High fat diet (HFD) was obtained from National centre for laboratory animal sciences (NCLAS), National Institute of Nutrition (NIN), Hyderabad, India. Diet composition is as follows, Casein (342 g), Cystine (30 g), Starch (172 g), Sucrose (50 g), Cellulose (50 g), G.N. Oil (25 g), Thallow (190 g), Mineral mixture (35 g), Vit. Mixture (10 g).

Experimental design

Rats were randomly divided in to six groups of six each. Group 1: Normal control group (NC), Group 2: High fat diet group (HFD), Group 3: HFD + Orlistat (30 mg/kg b.wt), Group 4: HFD + TPEE (100 mg/kg b.wt), Group 5: HFD + TPEE (150 mg/kg b.wt) and Group 6: HFD + TPEE (200 mg/kg b.wt).

Measurement of body and organ weights

At the end of the experimental period, rats were weighted and their weights noted. Later, they were fasted overnight, anaesthetized, sacrificed, organs (liver, spleen, kidney and testis were) were surgically removed, wet weights were measured with experimental electrical balance (Shimadzu) and stored at -80°C for further studies.

Estimation of liver lipid profiles

Liver tissues were washed in ice-cold saline (0.9%), blotted on absorbent paper and weighed. Hepatic lipids were extracted from 1 g liver with chloroform and methanol (2:1 v/v) according to the procedure of Folch [24]. Hepatic cholesterol, triglycerides and free fatty acids were estimated by commercially available kits (Randox Laboratories).

Assay of Liver antioxidant enzymes and lipid peroxidation

Superoxide dismutase (SOD) activity was determined spectrophotometrically according to a modified method of Beyer and Fridovich [25]. Liver tissue (100 mg) was lysed in isotonic buffer (10 mM Tric-HCl (pH 7.4), containing 200 mM mannitol, 50 mM sucrose and 1 mM EDTA) and centrifuged at 8000 rpm for 10 min. The supernatant was added to a reaction mixture containg PBS (pH 7.8), 0.1 mM EDTA, 12 mM L-methionine, 75 μM nitroblue tetrazolium (NBT) and 2 μM riboflavin to a total volume of 3 ml. The reaction mixture was kept under a fluorescent light for 15 min at 20-25°C and then measured spectrophotometrically at 240 nm. One unit of SOD represents the amount of enzyme required to inhibit the rate of NBT oxidation by 50%. The activity was expressed as units/mg protein.

Catalase (CAT) activity was measured by a modified method of Aebi [26]. Hydrogen peroxide (H2O2) decomposition by CAT was measured spectrophotometrically at 240 nm. The molar extinction coefficient of 0.043 mM-1 cm-1 was used to determine CAT activity. One unit of enzyme activity is equal to the micromole of H2O2 degraded per minute per milligram of protein (min-1 mg-1).

Lipid peroxidation was estimated by the modified method of Buege and Aust [27]. Briefly the MDA levels were estimated by measuring thiobarbituric acid reactive substances (TBARS) and expressed in terms of malodialdehyde (MDA) content. Before the assay, liver tissues were washed in 0.9% ice-cold saline, blotted on absorbent paper and weighed. Each sample was minced in a Tri-HCl buffer (pH 7.4) and homogenized. After centrifugation at 3000 g for 10 min at 4°C, the clear homogenate was used for biochemical assay. 125 μl of supernatant (S1) was mixed with 50 μl of PBS (pH7.4), 125 μl of 20% trichloroacetic acid containing 1% butylhydoxytoluene and centrifuged (1000 g, 10 min,4°C). Then 200 μl of supernatant (S2) was mixed with 40 μl of HCl (0.6 M) and 160 μl of Tris-Thiobarbituric acid (120 mM) and the mixture was heated at 80-85°C for 10-12 min. The absorbance was measured spectrophotometrically at 530 nm. The MDA levels were expressed as μmol/L/mg protein/mg tissue.

RNA extraction and semiquantitative RT-PCR

Total RNA was isolated from the liver tissue by using tri-reagent (Sigma-Aldrich, USA) according to manufacturer’s protocol and reverse transcribed to obtain cDNA using DNA synthesis kit (Applied Biosystems, Foster City, USA). 20 ng of cDNA was used for semi-quantitative PCR. The PCR amplification was performed for 38 cycles using the following cycling conditions: 30 sec of denaturation at 94°C, 30 sec of annealing at 59°C and 1 min of extension at 72°C, with following primers: FAS (F:ATGTGGTACGGAAGGTGGAG; R: TGGCTACCTTCGTCTGTGTG), AMPK-1α (F: GGTCCTGGTGGTTTCTGTTG; R: ATGATGTCAGATGGTGAATT) and RPL-19 (F: CGTCCTCCGCTGTGGTAAA; R: AGTACCCTTCCTCTTCCCTAT).

Western blot analysis

Liver tissue protein was extracted with lysis buffer (Sigma Aldrich, USA) and quatified using Bradford method. Equal amount of proteins were resolved on 10% SDS-PAGE gel and transferred to nitrocellulose membrane. To block nonspecific binding sites, blots were incubated at 4°C with 5% (v/v) skimmed milk for 1 hr followed by overnight incubation in primary antibodies of rabbit anti-FAS and mouse anti- β actin (Santa Cruz Biotechnology, USA) at 1:1000 dilution. The immunoreactive antigen was then recognized by incubation with Horse radish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology). Immunoreactive bands were visualized with chemiluminescence detection system (Thermo Fisher Scientific, USA).

Liver morphology and histopathology

Liver tissues from all groups of rats were collected and kept in 10% formalin solution. A small piece of tissue was sectioned with microtome, fixed on slides and stained using haematoxilin and eosin (H&E) staining procedures and observed under optical microscope.

Statistical analysis

Results are expressed as mean ± S.D (standard deviation). The statistical analysis of results was done by using t-test and one- way analysis (ANOVA) followed by Ducan’s. Values with p < 0.05 were considered to be statistically significant.



The authors are thankful to Prof. P. Kondaiah, Department of Molecular Reproduction Development and Genetics (MRDG), Indian Institute of Science, Bangalore, for providing the required facilities to carry out expression studies. Thanks to CSIR for Providing SRF.

Authors’ Affiliations

Department of Biochemistry, Sri Venkateswara University
Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science


  1. Feng L-J, Chen-Huan Y, Ying K-J, Hua J, Dai X-Y: Hypolipidemic and antioxidant effects of total flavonoids of Perilla frutescens leaves in hyperlipidemia rats induced by high-fat diet. Food Res Int. 2011, 44: 404-409. 10.1016/j.foodres.2010.09.035. 10.1016/j.foodres.2010.09.035View Article
  2. Niimi M, Keyamura Y, Nozako M, Koyama T, Kohashi M, Yasufuku R, Yoshikawa T, Fan J: Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. Lipids Health Dis. 2013, 12 (166): 1-8.
  3. Ok E, Do G-M, Lim Y, Park JE, Park YJ, Kwon O: Pomegranate vinegar attenuates adiposity in obese rats through coordinated control of AMPK signaling in the liver and adipose tissue. Lipids Health Dis. 2013, 12 (163): 1-8.
  4. Adams LA, Angulo P: Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005, 22: 1129-1133. 10.1111/j.1464-5491.2005.01748.xView ArticlePubMed
  5. Gauthier M-S, Favier R, Lavoie J-M: Time course of the development of non-alcoholic hepatic steatosis in response to high fat diet-induced obesity in rats. British J Nut. 2006, 95: 273-281. 10.1079/BJN20051635. 10.1079/BJN20051635View Article
  6. Bravo E, Palleschi S, Aspichueta P, Buque X, Rossi B, Cano A, Napolitano M, Ochoa B, Kathleen MB: High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the transsulphuration pathway. Lipids Health Dis. 2011, 10 (60): 1-6.
  7. Alsheikh-Ali AA, Kuvin JT, Karas RH: Risk of adverse events with fibrates. Am J Cardiol. 2004, 94: 935-938. 10.1016/j.amjcard.2004.06.033View ArticlePubMed
  8. Yun JW: Possible anti-obesity therapeutics from nature a review. Phytochemistry. 2010, 71: 1625-1641. 10.1016/j.phytochem.2010.07.011View ArticlePubMed
  9. Vasudeva N, Yadav N, Sharma SK: Natural products: a safest approach for obesity. Chin J Integr Med. 2012, 18 (6): 473-480. 10.1007/s11655-012-1120-0View ArticlePubMed
  10. Talwar S, Nandakumar K, Nayak PG: Anti-inflammatory activities of Terminalia paniculata bark extract against acute and chronic inflammation in rats. J Ethnopharmacol. 2011, 134 (2): 323-328. 10.1016/j.jep.2010.12.015View ArticlePubMed
  11. Nadkarni AK: Terminalia Paniculata Roxb. Indian Materia Medica. Edited by: Nadkarni KM. 1996, 931-Mumbai, India: Popular Prakashan, 3,
  12. Eesha BR, Mohanbabu Amberkar V, Meena Kumari K, Sarath babu Vijay M, Lalit M, Rajput R: Hepatoprotective activity of Terminalia paniculata against paracetamol induced hepatocellular damage in wistar rats. Asian Pac J Trop Med. 2011, 4 (6): 466-469. 10.1016/S1995-7645(11)60127-2View ArticlePubMed
  13. Subramaniam R, Aiyalu R, Manisenthikumar KT: Investigation of hyperglycemic, hyperlipidemic and antioxidant activity of aqueous extract of Terminalia paniculata bark in diabetic rats. Asian Pac J Trop Biomed. 2012, 2 (3): 262-268.
  14. Anonymous: The Wealth of India: Raw Material, Publication and Information Directorate. 1992, 345-346. New Delhi: CSIR.
  15. Agrawa S, Giriraj T, Kulkarni VN, Sharma A: Comparative study on the antioxidant activity of methanolic extracts of Terminalia paniculata and Madhuca longifolia. Free Radic Antioxid. 2011, 1 (4): 62-68.View Article
  16. Angulo P: Non alcoholic fatty liver disease. N Engl J Med. 2002, 346: 1221-1231. 10.1056/NEJMra011775View ArticlePubMed
  17. Yang SF, Tzang BS, Yang KT, Hsiao Y, Chang YY, Chan CH: Taurine alleviates dyslipidemia in hamsters fed a high fat/cholesterol diet. Food Chem. 2010, 120: 156-162. 10.1016/j.foodchem.2009.10.001. 10.1016/j.foodchem.2009.10.001View Article
  18. Sung YY, Yoon T, Kim SJ, Yang W-K, Kim HK: Anti-obesity activity of Allium fistulosum L. extract by down-regulation of the expression of lipogenic genes in high fat diet induced obese rats. Mol Med Rep. 2011, 4: 431-435.PubMed
  19. Evans P, Halliwell B: Micronutrients: Oxidabt/antioxidant satus. Br J Nutr. 2001, 85: S67-S74. 10.1079/BJN2000296View ArticlePubMed
  20. Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444: 860-867. 10.1038/nature05485View ArticlePubMed
  21. Shoelson SE, Herrero L, Naaz A: Obesity, inflammation and insulin resistance. Gastroenterology. 2007, 132: 2169-2180. 10.1053/j.gastro.2007.03.059View ArticlePubMed
  22. Berger JP: Role of PPARγ, transcriptional cofactors, and adiponectin in the regulation of nutrient metabolism, adipogenesis and insulin action: view from the chair. J Obes. 2005, 29: S3-S4.View Article
  23. Tamori Y, Masugi J, Nishino N, Kasuga M: The role of RRARγ in maintenance of the characteristics of mature 3 T3-L1 adipocytes. Diabetes. 2002, 51: 2045-2055. 10.2337/diabetes.51.7.2045View ArticlePubMed
  24. Folch J, Lees M, Sloane Stanly GH: A Simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 1957, 226 (1): 497-509.PubMed
  25. Beyer WE, : for superoxide dismutase activity: some large consequences of minor changes in conditions. Anal Biochem. 1987, 161: 559-566. 10.1016/0003-2697(87)90489-1View ArticlePubMed
  26. Aebi H: Catalase in vitro. Methods Enzymol. 1984, 105: 121-126.View ArticlePubMed
  27. Buege J, Aust SD, colowick Sp, Kaplan No: Microsomal Lipid Peroxidation. Methods in Enzymology. 1978, 302-311. New York: Acadomic press.


© Ramgopal et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.